Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy, with Focus on PM577 Prime Editor.
ByAinvest
Thursday, Oct 30, 2025 4:03 pm ET1min read
PRME--
Prime Medicine to host a virtual event on November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson's Disease. The company expects to file an IND/CTA for PM577, a Prime Editor for H1069Q-driven Wilson's Disease, in H1 2026, with initial clinical data expected in 2027. The event will feature presentations from the company's management team and Dr. Michael Schilsky, highlighting Prime Medicine's strategy to develop Prime Editors for genetic liver diseases.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet